Stock traders – Taiyo 33 http://taiyo-33.com/ Wed, 12 Jan 2022 08:42:04 +0000 en-US hourly 1 https://wordpress.org/?v=5.8.2 https://taiyo-33.com/wp-content/uploads/2021/11/taiyo-150x150.png Stock traders – Taiyo 33 http://taiyo-33.com/ 32 32 Stock Traders Buy Large Volume of Call Options on FG New America Acquisition (NYSE: OPFI) https://taiyo-33.com/stock-traders-buy-large-volume-of-call-options-on-fg-new-america-acquisition-nyse-opfi/ Wed, 12 Jan 2022 08:22:43 +0000 https://taiyo-33.com/stock-traders-buy-large-volume-of-call-options-on-fg-new-america-acquisition-nyse-opfi/ FG New America Acquisition Corp. (NYSE: OPFI) was the target of unusually heavy options trading activity on Monday. Traders bought 15,955 calls on the company. This represents an increase of 1,059% over the average daily volume of 1,377 call options. Meanwhile, Zacks Investment Research upgraded shares of FG New America Acquisition from a “strong sell” […]]]>

FG New America Acquisition Corp. (NYSE: OPFI) was the target of unusually heavy options trading activity on Monday. Traders bought 15,955 calls on the company. This represents an increase of 1,059% over the average daily volume of 1,377 call options.

Meanwhile, Zacks Investment Research upgraded shares of FG New America Acquisition from a “strong sell” rating to a “conservation” rating in a report released on Tuesday, October 19. Two equity research analysts rated the stock with a conservation rating and four gave the company’s stock a buy rating. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $ 11.40.

Hedge funds have recently increased or reduced their stakes in the company. Picton Mahoney Asset Management purchased a new equity stake in FG New America Acquisition in the 2nd quarter valued at $ 2,044,000. Penserra Capital Management LLC purchased a new equity stake in FG New America Acquisition in the 2nd quarter valued at $ 81,000. Qube Research & Technologies Ltd purchased a new equity stake in FG New America Acquisition in the 2nd quarter valued at $ 133,000. Bluefin Capital Management LLC increased its stake in the shares of FG New America Acquisition by 158.9% in the 2nd quarter. Bluefin Capital Management LLC now owns 45,000 shares of the company valued at $ 459,000 after purchasing an additional 27,621 shares in the last quarter. Finally, Beryl Capital Management LLC purchased a new stake in FG New America Acquisition in the second quarter for a value of $ 1,150,000.

NYSE OPFI opened at $ 5.76 on Wednesday. The company has a 50-day simple moving average of $ 4.76. FG New America Acquisition has a 12-month low of $ 4.11 and a 12-month high of $ 11.60.

(A d)

Whether you are looking to learn the basics of futures or are a seasoned veterinarian looking to hone your trading skills, our technical analysis guide has everything you need to be successful in today’s futures markets. hui!

FG New America Acquisition (NYSE: OPFI) last released its quarterly earnings data on Thursday, November 11. The company reported EPS of $ 0.21 for the quarter, beating the consensus estimate of $ 0.16 by $ 0.05. The company posted revenue of $ 91.98 million for the quarter, compared to $ 90.66 million expected by analysts. On average, sell-side analysts expect FG New America Acquisition to post 0.78 EPS for the current year.

About the acquisition of FG New America

FG New America Acquisition Corp. does not have important activities. The company intends to effect a merger, stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It aims to identify companies in the insurance and financial services sector, with a focus on the finTech and insuretech sectors.

Further reading: Stock market – What is a circuit breaker?

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in FG New America Acquisition now?

Before you consider acquiring FG New America, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and FG New America Acquisition was not on the list.

While FG New America Acquisition currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bids.

See the 5 actions here

]]>
Stock traders buy large volume of call options on international flavors and fragrances (NYSE: IFF) https://taiyo-33.com/stock-traders-buy-large-volume-of-call-options-on-international-flavors-and-fragrances-nyse-iff/ Sun, 09 Jan 2022 04:08:44 +0000 https://taiyo-33.com/stock-traders-buy-large-volume-of-call-options-on-international-flavors-and-fragrances-nyse-iff/ International Flavors & Fragrances Inc. (NYSE: IFF) was the target of unusual option trades on Friday. Stock traders bought 33,867 call options on the company. This represents an increase of approximately 2,422% over the average daily volume of 1,343 call options. A number of equity research analysts recently commented on the company. Mizuho raised its […]]]>

International Flavors & Fragrances Inc. (NYSE: IFF) was the target of unusual option trades on Friday. Stock traders bought 33,867 call options on the company. This represents an increase of approximately 2,422% over the average daily volume of 1,343 call options.

A number of equity research analysts recently commented on the company. Mizuho raised its price target on International Flavors & Fragrances from $ 154.00 to $ 156.00 and gave the company a “neutral” rating in a report released on Wednesday, November 10. JPMorgan Chase & Co. raised its price target for international flavors and fragrances from $ 163.00 to $ 165.00 and rated the stock “overweight” in a report released on Wednesday, November 10. Deutsche Bank Aktiengesellschaft raised its price target for international flavors and fragrances from $ 162.00 to $ 170.00 and gave the stock a “buy” rating in a report released on Friday, November 12. UBS Group lowered its price target for international flavors and fragrances from $ 187.00 to $ 185.00 and set a “buy” rating for the company in a report released Tuesday. Finally, Zacks Investment Research upgraded International Flavors & Fragrances from a “sell” rating to a “keep” rating and set a price target of $ 154.00 for the company in a report released on Tuesday, December 14. Four investment analysts gave the stock a conservation rating and nine gave the company a buy rating. According to MarketBeat data, the stock has a consensus rating of “Buy” and an average price target of $ 156.84.

IFF shares traded down $ 1.85 during the mid-day Friday session, reaching $ 141.97. The company’s shares had a trading volume of 1,601,863 shares, compared to its average volume of 1,287,113. International Flavors & Fragrances has a one-year low at $ 109.54 and a one-year high. at $ 157.08. The stock has a market cap of $ 36.14 billion, a P / E ratio of 115.42, a PEG ratio of 3.33 and a beta of 1.03. The company has a 50-day simple moving average of $ 146.46 and a two-hundred-day simple moving average of $ 146.41. The company has a current ratio of 1.99, a quick ratio of 1.32, and a debt ratio of 0.50.

(A d)

Whether you are looking to learn the basics of futures or are a seasoned veterinarian looking to hone your trading skills, our technical analysis guide has everything you need to be successful in today’s futures markets. hui!

International Flavors & Fragrances (NYSE: IFF) last released its quarterly earnings data on Monday, November 8. The specialty chemicals company reported earnings per share (EPS) of $ 1.47 for the quarter, beating Zacks’ consensus estimate of $ 1.39 by $ 0.08. International Flavors & Fragrances recorded a return on equity of 6.96% and a net margin of 2.50%. The company posted revenue of $ 3.07 billion in the quarter, compared to $ 3.02 billion expected by analysts. During the same period last year, the company posted earnings per share of $ 1.40. The company’s revenue increased 142.2% year-on-year. Research analysts predict that International Flavors & Fragrances will show 5.62 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 7. Shareholders of record on Tuesday, December 28 will receive a dividend of $ 0.79 per share. The ex-dividend date is Monday, December 27. This represents a dividend of $ 3.16 on an annualized basis and a dividend yield of 2.23%. International Flavors & Fragrances’ dividend payout ratio (DPR) is currently 256.91%.

Several hedge funds and other institutional investors have recently changed their positions in the company. People’s United Financial Inc. increased its stake in International Flavors & Fragrances by 1.5% during the 2nd quarter. People’s United Financial Inc. now owns 5,195 shares of the specialty chemicals company valued at $ 776,000 after acquiring 79 additional shares during the period. Johnson Investment Counsel Inc. increased its stake in International Flavors & Fragrances by 2.1% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 3,847 shares of the specialty chemicals company valued at $ 578,000 after acquiring 79 additional shares during the period. Pinnacle Associates Ltd. increased its stake in International Flavors & Fragrances by 3.9% during the 3rd quarter. Pinnacle Associates Ltd. now owns 2,080 shares of the specialty chemicals company valued at $ 278,000 after acquiring 79 additional shares during the period. Everett Harris & Co. CA increased its stake in International Flavors & Fragrances by 0.7% during the 3rd quarter. Everett Harris & Co. CA now owns 12,293 shares of the specialty chemicals company valued at $ 1,644,000 after acquiring 80 additional shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its stake in International Flavors & Fragrances by 3.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,997 shares of the specialty chemicals company valued at $ 448,000 after acquiring 96 additional shares during the period. Institutional investors hold 90.75% of the shares of the company.

About international flavors and fragrances

International Flavors & Fragrances, Inc is engaged in the manufacture and supply of flavors and fragrances used in food, beverages, personal care and household products. It operates through the following segments: Taste and Perfume. The Taste segment is sold to the food and beverage industries for use in consumer products such as prepared foods, beverages, dairy, food, and sweet products.

See also: Market Capitalization – What It Means For Investors

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in international flavors and fragrances now?

Before you consider International Flavors & Fragrances, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and International Flavors & Fragrances was not on the list.

While International Flavors & Fragrances currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

]]>
Stock traders buy high volume of call options on Vanda Pharmaceuticals (NASDAQ: VNDA) https://taiyo-33.com/stock-traders-buy-high-volume-of-call-options-on-vanda-pharmaceuticals-nasdaq-vnda/ Sun, 09 Jan 2022 04:08:44 +0000 https://taiyo-33.com/stock-traders-buy-high-volume-of-call-options-on-vanda-pharmaceuticals-nasdaq-vnda/ Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was the recipient of unusually large options trading on Friday. Stock traders bought 4,024 call options on the company. This is an increase of 1,070% over the average volume of 344 call options. Vanda Pharmaceuticals stock traded down $ 0.46 on Friday, reaching $ 15.38. The company’s shares had a […]]]>

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was the recipient of unusually large options trading on Friday. Stock traders bought 4,024 call options on the company. This is an increase of 1,070% over the average volume of 344 call options.

Vanda Pharmaceuticals stock traded down $ 0.46 on Friday, reaching $ 15.38. The company’s shares had a trading volume of 260,873 shares, compared to its average volume of 347,703. The company has a market capitalization of $ 856.85 million, a price-to-earnings ratio of 25.21 and a beta of 0.44. The company’s fifty-day average mobile price is $ 17.07, and its 200-day average mobile price is $ 17.57. Vanda Pharmaceuticals has a twelve month low of $ 13.36 and a twelve month high of $ 21.86.

Vanda Pharmaceuticals (NASDAQ: VNDA) last released its quarterly earnings data on Wednesday, November 3. The biopharmaceutical company reported EPS of $ 0.14 for the quarter, missing analyst consensus estimates of $ 0.20 per ($ 0.06). The company posted revenue of $ 70.10 million in the quarter, compared to analysts’ estimates of $ 73.50 million. Vanda Pharmaceuticals recorded a return on equity of 7.23% and a net margin of 12.77%. During the same period of the previous year, the company posted EPS of $ 0.11. As a group, equity research analysts predict that Vanda Pharmaceuticals will post earnings per share of 0.55 for the current year.

In addition, CEO Mihael Hristos Polymeropoulos sold 46,200 shares of Vanda Pharmaceuticals in a transaction dated Wednesday, December 1. The stock was sold for an average price of $ 16.00, for a total trade of $ 739,200.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 6.10% of the capital is held by insiders.

(A d)

This guide will help you identify and execute an options trading strategy that matches your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

A number of hedge funds and other institutional investors have recently increased or reduced their stakes in the stock. Meeder Asset Management Inc. increased its holdings of Vanda Pharmaceuticals shares by 3,824.8% in the third quarter. Meeder Asset Management Inc. now owns 4,435 shares of the biopharmaceutical company valued at $ 77,000 after acquiring an additional 4,322 shares in the last quarter. FORA Capital LLC purchased a new stake in Vanda Pharmaceuticals shares in the second quarter valued at approximately $ 129,000. Schonfeld Strategic Advisors LLC purchased a new equity stake in Vanda Pharmaceuticals in the third quarter valued at approximately $ 172,000. Grantham Mayo Van Otterloo & Co. LLC purchased a new stake in Vanda Pharmaceuticals shares in the third quarter valued at approximately $ 225,000. Finally, Profund Advisors LLC purchased a new stake in Vanda Pharmaceuticals shares in the second quarter valued at approximately $ 231,000. Institutional investors and hedge funds hold 98.42% of the company’s shares.

Meanwhile, Zacks Investment Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report released on Friday. One equity research analyst rated the stock with a sell rating, two issued a hold rating, and one issued a buy rating for the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $ 18.50.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals, Inc is engaged in the development and commercialization of therapies for significant unmet medical needs. The company intends to treat schizophrenia, jet lag disorders, atopic dermatitis, central nervous system disorders and circadian sleep rhythm disorders. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin and AQW051.

Featured article: What do investors mean by earnings per share?

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Vanda Pharmaceuticals now?

Before you consider Vanda Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the wider market takes hold … and Vanda Pharmaceuticals was not on the list.

While Vanda Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

]]>
Stock Traders Buy Large Volume 10x Genomic Puts (NASDAQ: TXG) https://taiyo-33.com/stock-traders-buy-large-volume-10x-genomic-puts-nasdaq-txg/ Sun, 09 Jan 2022 04:07:44 +0000 https://taiyo-33.com/stock-traders-buy-large-volume-10x-genomic-puts-nasdaq-txg/ 10x Genomics, Inc. (NASDAQ: TXG) saw unusually large options trading on Friday. Investors bought 4,599 put options on the stock. This is an 881% increase over the average daily volume of 469 puts. Separately, insider Benjamin J. Hindson sold 351 shares of the company in a transaction dated Monday, November 22. The stock was sold […]]]>

10x Genomics, Inc. (NASDAQ: TXG) saw unusually large options trading on Friday. Investors bought 4,599 put options on the stock. This is an 881% increase over the average daily volume of 469 puts.

Separately, insider Benjamin J. Hindson sold 351 shares of the company in a transaction dated Monday, November 22. The stock was sold for an average price of $ 148.38, for a total trade of $ 52,081.38. The transaction has been disclosed in a legal file with the Securities & Exchange Commission, which is available through this link. Additionally, insider Benjamin J. Hindson sold 41,666 shares of the company in a trade dated Monday, November 1. The stock was sold for an average price of $ 163.58, for a total value of $ 6,815,724.28. Disclosure of this sale can be found here. Insiders have sold 275,402 shares of the company valued at $ 42,024,650 in the past 90 days. Company insiders own 11.57% of the company’s shares.

Hedge funds and other institutional investors have recently increased or reduced their stakes in the stock. BlackRock Inc. increased its holdings of 10x Genomics shares by 42.2% during the 2nd quarter. BlackRock Inc. now owns 7,549,175 shares of the company valued at $ 1,478,280,000 after acquiring an additional 2,242,036 shares during the last quarter. Vigilant Capital Management LLC increased its stake in 10x Genomics by 2.4% during the 3rd quarter. Vigilant Capital Management LLC now owns 63,488 shares of the company valued at $ 9,243,000 after purchasing an additional 1,461 shares during the period. Bank of Montreal Can increased its holdings in 10x Genomics by 2.4% in the second quarter. Bank of Montreal Can now owns 37,839 shares of the company valued at $ 7,628,000 after purchasing an additional 889 shares during the period. Jasper Ridge Partners LP increased its holdings in 10x Genomics by 12.2% during the second quarter. Jasper Ridge Partners LP now owns 23,433 shares of the company valued at $ 4,589,000 after purchasing an additional 2,544 shares during the period. Finally, Tributary Capital Management LLC acquired a new position in 10x Genomics during the 3rd quarter valued at approximately $ 830,000. 77.50% of the shares are currently held by institutional investors.

(A d)

Whether you are looking to learn the basics of futures or are a seasoned veterinarian looking to hone your trading skills, our technical analysis guide has everything you need to be successful in today’s futures markets. hui!

Several research analysts recently commented on the company. Zacks Investment Research reduced 10x Genomics from a “buy” rating to a “keep” rating in a research report released on Friday, October 22. National Bank Financial began covering 10x Genomics in a research report on Thursday, September 16. They set a “sector performance” rating and a price target of $ 24.00 for the company. Morgan Stanley lowered its 10x Genomics price target from $ 215.00 to $ 205.00 and set an “overweight” rating on the stock in a research note on Thursday, November 4. Finally, Bank of America downgraded 10x Genomics from a “buy” rating to a “neutral” rating and set a price target of $ 180.00 for the share. in a research note on Tuesday, September 14. Three equity research analysts rated the stock with a conservation rating and five gave the stock a buy rating. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $ 169.29.

10x Genomics stock traded down $ 2.98 at midday on Friday, reaching $ 127.79. 600,521 shares of the company were traded, for an average volume of 663,524. The company has a fifty-day simple moving average of $ 149.88 and a 200-day simple moving average of $ 163.35. 10x Genomics has a 12-month low of $ 125.60 and a 12-month high of $ 208.99. The company has a market cap of $ 14.28 billion, a PE ratio of -30.21 and a beta of 1.38.

10x Genomics (NASDAQ: TXG) last released its results on Wednesday, November 3. The company reported ($ 0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($ 0.18) by $ 0.03. The company posted revenue of $ 125.30 million for the quarter, compared to a consensus estimate of $ 124.07 million. 10x Genomics recorded a negative return on equity of 6.30% and a negative net margin of 99.17%. In the same quarter of last year, the company posted ($ 0.33) EPS. As a group, research analysts expect 10x Genomics to post EPS of -0.42 for the current year.

About 10x the genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables and software for the analysis of biological systems in North America, Europe, Middle East, Africa, China and Asia-Pacific. The company provides chrome and chrome connection instruments, microfluidic chips, slides, reagents and other consumables.

See also: What should I know about analyst ratings?

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in 10x Genomics now?

Before you consider 10x genomics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the top five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes a hold of … and 10x Genomics was not on the list.

While 10x Genomics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

]]>
Stock Traders Buy Large Volume Concentrix Put Options (NASDAQ: CNXC) https://taiyo-33.com/stock-traders-buy-large-volume-concentrix-put-options-nasdaq-cnxc/ Sat, 08 Jan 2022 04:07:30 +0000 https://taiyo-33.com/stock-traders-buy-large-volume-concentrix-put-options-nasdaq-cnxc/ Concentrix Co. (NASDAQ: CNXC) saw unusually large options trading on Friday. Investors bought 2,411 put options on the stock. This represents a 1,997% increase over the average daily volume of 115 puts. A number of research analysts recently published reports on CNXC shares. Zacks Investment Research downgraded Concentrix from a “buy” rating to a “keep” […]]]>

Concentrix Co. (NASDAQ: CNXC) saw unusually large options trading on Friday. Investors bought 2,411 put options on the stock. This represents a 1,997% increase over the average daily volume of 115 puts.

A number of research analysts recently published reports on CNXC shares. Zacks Investment Research downgraded Concentrix from a “buy” rating to a “keep” rating in a report released on Tuesday, November 30. Barrington Research increased its price target on Concentrix from $ 182.00 to $ 202.00 and rated the stock as “outperforming” in a report released on Wednesday, September 29.

In other Concentrix news, director Dennis Polk sold 5,000 shares in a transaction dated Wednesday, December 1. The stock was sold for an average price of $ 168.49, for a total value of $ 842,450.00. The sale was disclosed in a file with the Securities & Exchange Commission, accessible through the SEC website. Insiders have sold 15,000 shares of the company valued at $ 2,613,050 in the past 90 days. Company insiders own 0.93% of the company’s shares.

Hedge funds and other institutional investors recently changed their holdings of stocks. SG Capital Management LLC acquired a new position in Concentrix during the third quarter valued at approximately $ 6,217,000. Boston Partners acquired a new equity stake in Concentrix in the second quarter valued at approximately $ 195,221,000. Brookfield Asset Management Inc. acquired a new equity interest in Concentrix in the second quarter valued at approximately $ 7,410,000. M&T Bank Corp acquired a new equity interest in Concentrix in the second quarter valued at approximately $ 211,000. Finally, Citigroup Inc. acquired a new equity interest in Concentrix in the second quarter valued at approximately $ 9,769,000. 75.55% of the shares are held by hedge funds and other institutional investors.

(A d)

As of December 13, 2021, Bitcoin was over $ 40,000. In fact, some experts believe that Bitcoin could replace gold in the future.
But most people aren’t even aware of these 5 stocks in the crypto space …

NASDAQ CNXC traded at $ 11.87 during Friday trading hours, reaching $ 164.47. 260,635 shares of the company traded hands, compared to its average volume of 256,227. The company’s 50-day moving average is $ 176.97 and its 200-day moving average is $ 171.52 . Concentrix has a twelve month low of $ 101.94 and a twelve month high of $ 191.35. The company has a debt to equity ratio of 0.34, a quick ratio of 1.64, and a current ratio of 1.64. The stock has a market cap of $ 8.61 billion and a price-to-earnings ratio of 24.96.

Concentrix Company Profile

Concentrix Corporation provides technology-infused customer experience solutions around the world. It provides CX process optimization, technology innovation, front-office and back-office automation, business analysis and transformation services. The company also offers customer lifecycle management; customer experience / user experience strategy and design; digital transformation; and voice of the customer and analytics solutions.

Further reading: market indices

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Concentrix now?

Before you consider Concentrix, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the top five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Concentrix was not on the list.

While Concentrix currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

]]>
Stock traders buy large volume of put options on Humana (NYSE: HUM) https://taiyo-33.com/stock-traders-buy-large-volume-of-put-options-on-humana-nyse-hum/ Fri, 07 Jan 2022 15:52:55 +0000 https://taiyo-33.com/stock-traders-buy-large-volume-of-put-options-on-humana-nyse-hum/ Humana Inc. (NYSE: HUM) was the target of unusually heavy options trading activity on Friday. Traders bought 3,495 puts on the company. This represents a 65% increase over the average daily volume of 2,114 puts. HUM has been the subject of several research reports. Citigroup raised its price target for Humana shares from $ 510.00 […]]]>

Humana Inc. (NYSE: HUM) was the target of unusually heavy options trading activity on Friday. Traders bought 3,495 puts on the company. This represents a 65% increase over the average daily volume of 2,114 puts.

HUM has been the subject of several research reports. Citigroup raised its price target for Humana shares from $ 510.00 to $ 528.00 and assigned a “buy” rating to the stock in a research report on Tuesday, November 9. Royal Bank of Canada raised its price target for Humana shares from $ 479.00 to $ 525.00 and assigned the stock an “outperformance” rating in a research report released on Thursday, November 4. Oppenheimer raised its price target on Humana shares from $ 480.00 to $ 510.00 and rated the stock as “outperforming” in a research report released Thursday, November 4. Bank of America raised its price target for Humana shares from $ 505.00 to $ 530.00 and gave the company a “buy” rating in a research report released Thursday, November 4. Finally, the Goldman Sachs group assumed coverage of Humana’s shares in a research report on Tuesday, December 14. They issued a “neutral” rating and a target price of $ 472.00 on the stock. Seven investment analysts rated the stock with a conservation rating and thirteen gave the stock a buy rating. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $ 498.93.

In other Humana news, CEO Bruce D. Broussard sold 50,006 shares of the company in a trade on Friday, November 5. The shares were sold for an average price of $ 454.70, for a total value of $ 22,737,728.20. The transaction was disclosed in a legal file with the Securities & Exchange Commission, accessible through this hyperlink. Company insiders own 0.40% of the company’s shares.

(A d)

Whether you are looking to learn the basics of futures or are a seasoned veterinarian looking to hone your trading skills, our technical analysis guide has everything you need to be successful in today’s futures markets. hui!

Several institutional investors have recently changed their holdings in HUM. Viking Global Investors LP increased its position in Humana by 411.2% during the 3rd quarter. Viking Global Investors LP now owns 3,007,133 shares of the insurance provider valued at $ 1,170,226,000 after purchasing an additional 2,418,848 shares in the last quarter. FMR LLC increased its position in Humana by 18.7% during the 2nd quarter. FMR LLC now owns 10,241,494 shares of the insurance provider valued at $ 4,534,114,000 after purchasing an additional 1,612,251 shares during the last quarter. Amundi took a new stake in Humana during the second quarter for a value of approximately $ 393,330,000. Wellington Management Group LLP increased its position in Humana by 10.7% during the 3rd quarter. Wellington Management Group LLP now owns 6,465,032 shares of the insurance provider valued at $ 2,515,867,000 after purchasing an additional 626,652 shares in the last quarter. Finally, First Trust Advisors LP increased its position in Humana by 186.1% during the second quarter. First Trust Advisors LP now owns 690,050 shares of the insurance provider valued at $ 305,499,000 after purchasing an additional 448,859 shares in the last quarter. Institutional investors hold 91.75% of the company’s shares.

NYSE: HUM traded down $ 13.29 during Friday’s midday session, reaching $ 354.24. 61,433 shares of the stock traded hands, up from its average volume of 2,412,183. The company has a fifty-day moving average of $ 446.92 and a 200-day moving average of $ 434.17. Humana has a 12 month low of $ 359.28 and a 12 month high of $ 475.44. The company has a debt to equity ratio of 0.70, a quick ratio of 1.72, and a current ratio of 1.72. The stock has a market cap of $ 45.53 billion, a P / E ratio of 17.38, a PEG ratio of 1.68 and a beta of 0.94.

Humana (NYSE: HUM) last released its quarterly results on Wednesday, November 3. The insurance provider reported EPS of $ 4.83 for the quarter, beating the Zacks’ consensus estimate of $ 4.61 by $ 0.22. Humana had a net margin of 3.30% and a return on equity of 14.95%. The company posted revenue of $ 20.70 billion in the quarter, compared to $ 20.91 billion according to analysts’ estimates. During the same period of the previous year, the company posted EPS of $ 3.08. The company’s revenue increased 3.1% compared to the same quarter last year. On average, analysts predict that Humana will post 20.54 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 28. Shareholders of record on Friday, December 31 will receive a dividend of $ 0.70. The ex-dividend date for this dividend is Thursday, December 30. This represents an annualized dividend of $ 2.80 and a return of 0.79%. Humana’s dividend payout ratio (DPR) is currently 13.52%.

About Humana

Humana Inc is engaged in the provision of health insurance services. The company operates in the following segments: retail, group and specialty services, and healthcare. The Retail segment includes products sold at retail to individuals, including medical and extended benefit plans such as Medicare and state-based Medicaid contracts.

See also: Crypto-currencies

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Humana now?

Before you consider Humana, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the top five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Humana was not on the list.

While Humana currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

]]>
Stock traders buy high volume of put options on JOANN (NASDAQ: JOAN) https://taiyo-33.com/stock-traders-buy-high-volume-of-put-options-on-joann-nasdaq-joan/ Fri, 07 Jan 2022 07:28:25 +0000 https://taiyo-33.com/stock-traders-buy-high-volume-of-put-options-on-joann-nasdaq-joan/ JOANN Inc. (NASDAQ: JOAN) was the recipient of unusually large options trading on Thursday. Traders bought 2,948 puts on the company. This represents a 2.100% increase over the average volume of 134 puts. Meanwhile, CFO Matthew B. Susz sold 78,627 shares in a trade on Wednesday, December 8. The stock was sold for an average […]]]>

JOANN Inc. (NASDAQ: JOAN) was the recipient of unusually large options trading on Thursday. Traders bought 2,948 puts on the company. This represents a 2.100% increase over the average volume of 134 puts.

Meanwhile, CFO Matthew B. Susz sold 78,627 shares in a trade on Wednesday, December 8. The stock was sold for an average price of $ 9.90, for a total value of $ 778,407.30. The sale was disclosed in a legal file with the SEC, accessible through this link. In addition, CEO Wade D. Miquelon bought 55,000 shares of the company in a transaction that took place on Tuesday, December 7th. The stock was purchased at an average price of $ 9.33 per share, for a total trade of $ 513,150.00. Disclosure of this purchase can be found here.

Several hedge funds have recently increased or reduced their holdings in JOAN. UBS Group AG increased its participation in JOANN shares by 2,122.0% in the third quarter. UBS Group AG now owns 2,222 shares of the company valued at $ 25,000 after purchasing an additional 2,122 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in JOANN shares during the 2nd quarter valued at $ 70,000. Pinz Capital Management LP purchased a new position in JOANN shares during the 2nd quarter valued at $ 117,000. Lombard Odier Asset Management USA Corp bought a new position in JOANN shares during the 3rd quarter valued at $ 123,000. Finally, the New York State Common Retirement Fund purchased a new position in JOANN shares during the second quarter valued at $ 156,000. 91.11% of the shares are currently held by institutional investors.

(A d)

People have done it with Amazon, Uber, Apple, and many other disruptive actions.

And now investors are betting big on a biotech company behind a shocking breakthrough medical discovery …

JOANN stock opened at $ 10.57 on Friday. The company’s 50-day simple moving average is $ 10.27 and its 200-day simple moving average is $ 12.23. The company has a current ratio of 1.38, a quick ratio of 0.18, and a debt ratio of 5.82. The company has a market capitalization of $ 435.28 million and a PE ratio of 5.08. JOANN has a one-year minimum at $ 8.51 and a one-year maximum at $ 17.50.

JOANN (NASDAQ: JOAN) last released its quarterly results on Wednesday, December 1. The company reported EPS of $ 0.73 for the quarter, beating the Zacks’ consensus estimate of $ 0.62 of $ 0.11. The company posted revenue of $ 611.00 million for the quarter, compared to analysts’ estimates of $ 620.84 million. JOANN had a net margin of 3.23% and a return on equity of 68.21%. The company’s revenue for the quarter was down 14.4% from the same quarter last year. In the same quarter of the previous year, the company achieved EPS of $ 1.84. Research analysts predict that JOANN will post earnings per share of 1.68 for the current year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 29. Shareholders of record on Wednesday, December 15 received a dividend of $ 0.10. This represents a dividend of $ 0.40 on an annualized basis and a dividend yield of 3.78%. The ex-dividend date was Tuesday, December 14. JOANN’s payout rate is 19.23%.

JOAN has been the subject of several analyst reports. Telsey Advisory Group lowered its price target on JOANN from $ 14.00 to $ 11.00 and established a “market performance” rating for the company in a research report released on Wednesday, December 1. Zacks Investment Research downgraded JOANN from a “hold” rating to a “buy” rating and set a target price of $ 12.00 for the company in a research report released on Thursday, December 9. Barclays lowered its price target on JOANN from $ 11.00 to $ 10.00 and set an “underweight” rating for the company in a research report published on Monday, December 6. Finally, Wells Fargo & Company downgraded JOANN from an “overweight” rating to an “on par” rating and lowered its target price for the company from $ 15.00 to $ 10.00 in a research report on Friday. December 3. One investment analyst gave the stock a sell rating, two assigned a conservation rating, and seven assigned a buy rating to the company. Based on data from MarketBeat.com, JOANN has a consensus rating of “Buy” and a consensus price target of $ 13.89.

About JOANN

JOANN Inc operates as a specialty retailer of sewing, arts and crafts products in the United States. Its products in the sewing category include cotton fabrics; warm fabrics, such as fleece and flannel fabrics; interior decoration and utility fabrics and accessories; fashion fabrics and sportswear; fabrics for special occasions; seasonally themed and licensed fabric designs; and sewing supplies including cutting tools, threads, zippers, trims, ribbons, pins, rubber bands and buttons, as well as patterns for sewing projects.

Recommended story: breaking actions

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in JOANN now?

Before you consider JOANN, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the top five stocks that top analysts quietly whisper to their clients to buy now before the wider market takes hold … and JOANN was not on the list.

While JOANN currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bids.

See the 5 actions here

]]>
Stock traders buy large volume of call options on NRG Energy (NYSE: NRG) https://taiyo-33.com/stock-traders-buy-large-volume-of-call-options-on-nrg-energy-nyse-nrg/ Mon, 03 Jan 2022 20:23:26 +0000 https://taiyo-33.com/stock-traders-buy-large-volume-of-call-options-on-nrg-energy-nyse-nrg/ NRG Energy, Inc. (NYSE: NRG) saw unusual options trading on Monday. Stock traders acquired 21,978 call options on the company. This is an increase of 831% over the typical daily volume of 2,361 call options. In addition, Vice President Christopher Moser acquired 1,911 shares of the company in a transaction on Monday, November 22. The […]]]>

NRG Energy, Inc. (NYSE: NRG) saw unusual options trading on Monday. Stock traders acquired 21,978 call options on the company. This is an increase of 831% over the typical daily volume of 2,361 call options.

In addition, Vice President Christopher Moser acquired 1,911 shares of the company in a transaction on Monday, November 22. The shares were purchased at an average cost of $ 36.63 per share, for a total value of $ 69,999.93. The acquisition has been disclosed in a legal file with the Securities & Exchange Commission, which is available at this link. 0.83% of the shares are currently owned by insiders.

Large investors have recently bought and sold shares in the company. Van ECK Associates Corp acquired a new position in NRG Energy during the 2nd quarter valued at $ 26,000. First Horizon Advisors Inc. increased its position in shares of NRG Energy by 112.5% ​​during the 3rd quarter. First Horizon Advisors Inc. now owns 663 shares of the utility provider valued at $ 83,000 after acquiring 351 additional shares in the last quarter. Larson Financial Group LLC purchased a new stake in NRG Energy shares during the 3rd quarter valued at $ 28,000. Hexagon Capital Partners LLC increased its position in NRG Energy shares by 68.2% during the 2nd quarter. Hexagon Capital Partners LLC now owns 720 shares of the utility provider valued at $ 29,000 after acquiring 292 more shares in the last quarter. Finally, Koshinski Asset Management Inc. purchased a new equity stake in NRG Energy during the 3rd quarter for a value of $ 32,000. 97.91% of the shares are currently held by hedge funds and other institutional investors.

(A d)

Through Berkshire Hathaway… Warren Buffett recently gave up on Apple stock for $ 800 million…

And bought this instead!

NRG shares traded down $ 0.25 on Monday, reaching $ 42.83. The company’s shares had a trading volume of 126,697 shares, compared to its average volume of 2,793,587. The company has a market capitalization of $ 10.49 billion, a PE ratio of 4.29, a ratio of PEG of 0.17 and a beta of 0.89. The company has a debt to equity ratio of 1.95, a current ratio of 1.21, and a rapid ratio of 1.18. NRG Energy has a 52-week low of $ 31.94 and a 52-week high of $ 46.10. The company has a 50-day moving average price of $ 38.70 and a 200-day moving average price of $ 40.75.

NRG Energy (NYSE: NRG) last reported its results on Thursday, November 4. The utility provider reported EPS of $ 6.60 for the quarter, beating the consensus estimate of $ 2.08 by $ 4.52. The company posted revenue of $ 6.61 billion for the quarter, compared to a consensus estimate of $ 3.85 billion. NRG Energy recorded a return on equity of 80.94% and a net margin of 11.11%. NRG Energy’s revenues increased 135.3% compared to the same quarter last year. During the same period of the previous year, the company made EPS of $ 1.02. On average, stock analysts predict that NRG Energy will post 5.73 EPS for the current year.

NRG Energy said its board of directors launched a share buyback program on Monday, December 6 that allows the company to repurchase $ 1.00 billion of outstanding shares. This buyback authorization allows the utility provider to buy up to 10.7% of its shares through open market purchases. Share buyback programs often indicate that the board of directors of the company feels that its shares are undervalued.

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 15. Shareholders of record on Monday, November 1 received a dividend of $ 0.325 per share. This represents an annualized dividend of $ 1.30 and a return of 3.04%. The ex-dividend date of this dividend was Friday October 29. NRG Energy’s dividend payout ratio is 13.04%.

NRG Energy Company Profile

NRG Energy, Inc. engages in the production, sale and distribution of energy and energy services. It operates through the following segments: production, retail and enterprise. The Generation segment includes all activities of power plants, national and international, as well as renewable energies. The Retail segment includes mass customers and business solutions, as well as other distributed and reliable products.

Featured article: Green investing

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in NRG Energy now?

Before you consider NRG Energy, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and NRG Energy was not on the list.

While NRG Energy currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

]]>
Stock traders buy high volume of call options on Allegiant Travel (NASDAQ: ALGT) https://taiyo-33.com/stock-traders-buy-high-volume-of-call-options-on-allegiant-travel-nasdaq-algt/ Mon, 03 Jan 2022 19:44:43 +0000 https://taiyo-33.com/stock-traders-buy-high-volume-of-call-options-on-allegiant-travel-nasdaq-algt/ Allegiant Travel (NASDAQ: ALGT) received unusual option trades on Monday. Stock traders bought 2,294 call options on the company. This represents an increase of 573% over the typical daily volume of 341 call options. Separately, insider Rebecca Aretos sold 182 shares of the company in a transaction that took place on Tuesday, October 26. The […]]]>

Allegiant Travel (NASDAQ: ALGT) received unusual option trades on Monday. Stock traders bought 2,294 call options on the company. This represents an increase of 573% over the typical daily volume of 341 call options.

Separately, insider Rebecca Aretos sold 182 shares of the company in a transaction that took place on Tuesday, October 26. The stock was sold for an average price of $ 182.45, for a total value of $ 33,205.90. The transaction has been disclosed in a legal file with the SEC, which is available through this link. Company insiders own 16.70% of the company’s shares.

A number of large investors have recently bought and sold shares of ALGT. Amundi Pioneer Asset Management Inc. acquired in the first quarter a new position in Allegiant Travel valued at $ 155,000. Victory Capital Management Inc. increased its holdings of Allegiant Travel shares by 7.8% during the second quarter. Victory Capital Management Inc. now owns 2,128 shares of the transportation company valued at $ 413,000 after purchasing 154 additional shares in the last quarter. Russell Investments Group Ltd. increased its holdings of Allegiant Travel shares by 10.0% in the second quarter. Russell Investments Group Ltd. now owns 36,257 shares of the transportation company valued at $ 7,031,000 after purchasing an additional 3,286 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings of Allegiant Travel shares by 7.1% during the second quarter. Envestnet Asset Management Inc. now owns 5,180 shares of the transportation company valued at $ 1,005,000 after purchasing 343 additional shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Allegiant Travel shares by 28.3% during the second quarter. American Century Companies Inc. now owns 1,820 shares of the transportation company valued at $ 353,000 after purchasing an additional 401 shares in the last quarter. 85.98% of the shares are currently held by hedge funds and other institutional investors.

(A d)

Why is Jeff Brown throwing away a perfectly good $ 1,000 iPhone?

According to him, Apple is about to make a critical announcement that will send shockwaves on Wall Street.

A number of research firms have commented on ALGT. Susquehanna reduced its price target on Allegiant Travel from $ 255.00 to $ 240.00 and rated the stock “positive” in a Friday October 29th research note. Raymond James reduced his price target on Allegiant Travel from $ 260.00 to $ 235.00 and set a “strong buy” rating on the stock in a research note on Thursday, October 28. Wolfe Research downgraded Allegiant Travel from an “outperformance” rating to a “peer performance” rating in a Wednesday, October 6 research note. They noted that the move was an appraisal call. Susquehanna Bancshares reduced her price target on Allegiant Travel from $ 255.00 to $ 240.00 and rated the stock “positive” in a Friday October 29th research note. Finally, Morgan Stanley lowered its price target on Allegiant Travel from $ 300.00 to $ 280.00 and set an “overweight” rating on the stock in a Tuesday, November 16 research note. Two investment analysts assigned a conservation rating to the stock, nine issued a buy rating and one assigned a high buy rating to the stock. According to data from MarketBeat.com, Allegiant Travel has an average “Buy” rating and an average target price of $ 245.75.

NASDAQ: ALGT traded up $ 4.23 during trading hours on Monday, reaching $ 191.27. The company’s shares had a traded volume of 10,262 shares, compared to an average volume of 171,698. The stock has a market cap of $ 3.46 billion, a P / E ratio of 30.72 and a beta of 1.61. The stock has a fifty-day moving average of $ 183.54 and a 200-day moving average of $ 189.34. The company has a current ratio of 1.91, a quick ratio of 1.87 and a debt ratio of 1.20. Allegiant Travel has a 52 week low of $ 163.60 and a 52 week high of $ 271.29.

Allegiant Travel (NASDAQ: ALGT) last released its results on Tuesday, October 26. The transportation company reported EPS of $ 0.66 for the quarter, beating the consensus estimate of $ 0.64 by $ 0.02. The company posted revenue of $ 459.47 million for the quarter, compared to $ 451.35 million according to analysts’ estimates. Allegiant Travel recorded a negative return on equity of 0.35% and a net margin of 7.71%. Allegiant Travel revenue for the quarter increased 128.6% compared to the same quarter last year. In the same quarter of the previous year, the company posted earnings per share ($ 4.28). On average, sell-side analysts predict that Allegiant Travel will post earnings per share of 1.94 for the current year.

Allegiant Travel Company Profile

Allegiant Travel Co is engaged in the provision of travel services. It includes scheduled service air transport, air travel related travel products and services, third party travel products and fixed rate contract air transport. It operates through the following segments: Airline, Sunseeker Resort and Other Non-Airlines.

Further reading: How is the Consumer Price Index (CPI) calculated?

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Allegiant Travel now?

Before you consider Allegiant Travel, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of… and Allegiant Travel was not on the list.

While Allegiant Travel currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

]]>
Stock traders buy large volume of call options from Theravance Biopharma (NASDAQ: TBPH) https://taiyo-33.com/stock-traders-buy-large-volume-of-call-options-from-theravance-biopharma-nasdaq-tbph/ Sun, 02 Jan 2022 18:33:45 +0000 https://taiyo-33.com/stock-traders-buy-large-volume-of-call-options-from-theravance-biopharma-nasdaq-tbph/ Theravance Biopharma, Inc. (NASDAQ: TBPH) was the target of unusual options trading activity on Monday. Stock traders acquired 4,344 call options on the stock. This represents an increase of approximately 356% over the average volume of 952 call options. NASDAQ TBPH shares traded up $ 1.20 in Monday’s midday session, reaching $ 12.25. 456,201 shares […]]]>

Theravance Biopharma, Inc. (NASDAQ: TBPH) was the target of unusual options trading activity on Monday. Stock traders acquired 4,344 call options on the stock. This represents an increase of approximately 356% over the average volume of 952 call options.

NASDAQ TBPH shares traded up $ 1.20 in Monday’s midday session, reaching $ 12.25. 456,201 shares of the stock traded for an average volume of 703,828. The company has a market capitalization of $ 902.80 million, a PE ratio of -3.49 and a beta of 0.84. Theravance Biopharma has a one-year minimum of $ 6.10 and a one-year maximum of $ 22.74. The stock has a 50-day moving average of $ 9.03.

Theravance Biopharma (NASDAQ: TBPH) last released its quarterly results on Tuesday, November 2. The biopharmaceutical company reported ($ 0.48) earnings per share for the quarter, beating Thomson Reuters consensus estimate of ($ 0.60) by $ 0.12. The company posted revenue of $ 13.19 million for the quarter, compared to analysts’ expectations of $ 13.55 million. In the same quarter of the previous year, the company posted EPS ($ 1.16). Analysts expect Theravance Biopharma to post earnings per share of -2.84 for the current year.

A number of analysts recently commented on the headline. SVB Leerink lowered its price target on Theravance Biopharma shares from $ 29.00 to $ 10.00 and established an “outperformance” rating on the share in a report released on Thursday, September 16. Cowen reduced his target price on Theravance Biopharma from $ 14.00 to $ 8.00 and established a “market performance” rating for the company in a research report released on Wednesday, September 15. Zacks Investment Research downgraded Theravance Biopharma from a “buy” rating to a “keep” rating and set a target price of $ 7.50 for the company. in a research report on Wednesday, September 22. Robert W. Baird reduced his target price on Theravance Biopharma from $ 10.00 to $ 7.00 and established a “neutral” rating for the company in a research report on Thursday, September 16. Finally, Needham & Company LLC downgraded Theravance Biopharma from a “buy” rating to a “keep” rating in a research report released on Wednesday, September 15. Two analysts rated the stock with a sell rating, five issued a conservation rating and two gave the company a buy rating. According to data from MarketBeat.com, Theravance Biopharma currently has a consensus rating of “Hold” and a consensus target price of $ 10.50.

(A d)

According to Bloomberg NEF, turning the world into “all green energy” could cost around $ 173 trillion. And without this rare metal, going green would be IMPOSSIBLE. This is why there is a literal “gold rush” to find it. (TIP: these are not electric vehicles, nuclear power, or wind power).

A number of hedge funds have recently increased or reduced their stakes in the company. Madison Avenue Partners LP acquired a new stake in Theravance Biopharma in the third quarter for a value of approximately $ 36,478,000. Point72 Asset Management LP acquired a new stake in Theravance Biopharma in the third quarter for a value of approximately $ 25,201,000. Camber Capital Management LP acquired a new stake in Theravance Biopharma in the third quarter for a value of approximately $ 18,500,000. Maven Securities LTD acquired a new stake in Theravance Biopharma in the second quarter for a value of approximately $ 20,125,000. Finally, FMR LLC increased its stake in Theravance Biopharma shares by 10.9% during the second quarter. FMR LLC now owns 10,791,863 shares of the biopharmaceutical company valued at $ 156,698,000 after purchasing an additional 1,061,697 shares during the period. Institutional investors and hedge funds hold 72.77% of the company’s shares.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ selective drugs. Its goal is to launch a new generation of small molecule drugs designed to better meet the needs of patients. His research focuses on the areas of inflammation and immunology. In pursuit of its goal, Theravance Biopharma applies knowledge and innovation at every stage of its activities and uses its internal capacities and those of partners around the world.

Featured article: If I buy stocks through a brokerage account, am I the registered owner?

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Theravance Biopharma now?

Before you consider Theravance Biopharma, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the top five stocks that top analysts quietly whisper to their clients to buy now before the market in general takes hold … and Theravance Biopharma was not on the list.

While Theravance Biopharma currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

]]>